title: An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.
authors.affiliation: a Department of Pathology , Seoul National University Hospital, Seoul National University College of Medicine , Seoul , Republic of Korea ;|b The Tumor Immunity Medical Research Center, Cancer Research Center, Seoul National University College of Medicine , Seoul , Republic of Korea ;
authors.forename: Soo Jeong
authors.initials: SJ
authors.lastname: Nam
authors.affiliation: a Department of Pathology , Seoul National University Hospital, Seoul National University College of Medicine , Seoul , Republic of Korea ;|b The Tumor Immunity Medical Research Center, Cancer Research Center, Seoul National University College of Medicine , Seoul , Republic of Korea ;
authors.forename: Sehui
authors.initials: S
authors.lastname: Kim
authors.affiliation: c Department of Pathology , Seoul National University Bundang Hospital , Seongnam-Si , Republic of Korea ;
authors.forename: Jin Ho
authors.initials: JH
authors.lastname: Paik
authors.affiliation: d Department of Internal Medicine , Seoul National University Hospital, Seoul National University College of Medicine , Seoul , Republic of Korea.
authors.forename: Tae Min
authors.initials: TM
authors.lastname: Kim
authors.affiliation: d Department of Internal Medicine , Seoul National University Hospital, Seoul National University College of Medicine , Seoul , Republic of Korea.
authors.forename: Dae Seog
authors.initials: DS
authors.lastname: Heo
authors.affiliation: a Department of Pathology , Seoul National University Hospital, Seoul National University College of Medicine , Seoul , Republic of Korea ;|b The Tumor Immunity Medical Research Center, Cancer Research Center, Seoul National University College of Medicine , Seoul , Republic of Korea ;
authors.forename: Chul Woo
authors.initials: CW
authors.lastname: Kim
authors.affiliation: a Department of Pathology , Seoul National University Hospital, Seoul National University College of Medicine , Seoul , Republic of Korea ;|b The Tumor Immunity Medical Research Center, Cancer Research Center, Seoul National University College of Medicine , Seoul , Republic of Korea ;
authors.forename: Yoon Kyung
authors.initials: YK
authors.lastname: Jeon
mesh_terms: D015703:Antigens, CD / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000378:metabolism*; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000378:metabolism; D000069283:Rituximab / Q000008:administration & dosage; D060149:Tetraspanin 30 / Q000378:metabolism; D059016:Tumor Microenvironment; D014750:Vincristine / Q000008:administration & dosage; D000098902:CD163 Antigen
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000098902:CD163 Antigen; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D011956:Receptors, Cell Surface; D060149:Tetraspanin 30; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone